Antihypertensive Efficacy of a Triple Fixed-Dose Combination of Perindopril, Indapamide, and Amlodipine: Clinical Effectiveness in Ambulatory Practice (Results of the PETRA Study)

Most patients with arterial hypertension (AH) for successful long-term blood pressure (BP) control require combination of antihypertensive drugs acting on various target organs. Accumulated experience shows that about 30 % of patients require combination therapy with 3 drugs from different pharmacological classes. Efficacy of BP control in real clinical practice with the use of various doses of perindopril, indapamide, and amlodipine as components of taken once-daily triple fixed combination was assessed in the 3-months prospective observational open-label PETRA study. In this study data of office BP measurements and 24-hour ambulatory BP monitoring (ABPM) were obtained from 11209 ambulatory patients (47.6 % women) with AH. Initial mean office BP (BPmoff) was 156.58±16.10 / 91.56±9.33 mm Hg, AH duration – 9.48±7.19 years. After switching to triple fixed dose combination of perindopril, indapamide, and amlodipine BPmoff decreased by 24.81±15.47 / 11.41±9.90 mm Hg (p<0.0001). Doses of perindopril, indapamide, and amlodipine in combination at the final visit were 5 / 1.25 / 5, 10 / 2.5 / 5, and 10 / 2.5 / 10 mg. 24-hour ambulatory BP monitoring (ABPM) was carried out in 76 patients. Mean 24-hour BP lowed from mean 155.51±17.43 / 85.28±11.48 down to 134.63±12.51 / 77.83±8.99 mm Hg (p<0.0001). Clinically relevant improvement of a number of parameters of metabolism occurred after 3 months of the study (in particular, lowering of levels of total and low-density lipoprotein cholesterol [–8.6 and – 11.4 %, respectively], triglycerides [–12,1 %], fasting blood glucose [–6.6 %]). Thus, results of the PETRA study confirmed 24-hour long antihypertensive efficacy of triple fixed dose combination of perindopril, indapamide, and amlodipine. This drug combination can present novel possibility in treatment of patients with AH who have not achieved target BP values on preceding dual combination therapy and fully corresponds with the single pill concept for formation of adherence to therapy.

ambulatory blood pressure monitoring, metabolic parameters, non-interventional study, office blood pressure, triple fixed combination

1. Abraham G., Dezsi C. A. The Antihypertensive Efficacy of the Triple Fixed Combination of Perindopril, Indapamide, and Amlodipine: The Results of the PET^A Study. Adv Ther 2017;34 (7):1753-1763. DOI: 10.1007/s12325-017-0572-1.

2. Bakris GL. The importance of blood pressure control in the patient with diabetes. Am J Med 2004;116 (5A): 30S - 38S.

3. Dahlof B., Sever P. S., Poulter N. R. et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicenter randomised controlled trial. Lancet 2005;366:895-906.

4. Jamerson K., Weber M. A., Bakris G. L. et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med 2008;359:2417-2428.

5. Gradman A. H. Rationale for triple-combination therapy for management of high blood pressure. J Clin Hypertens (Greenwich) 2010;12:869-878.

6. Mancia G., Robert Fagard R., Narkiewicz K. et al. 2013 ESH/ESC Guidelines for themanagement of arterial hypertension. The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2013;34:2159-2219.

7. NICE. Clinical guideline 127. Hypertension in adults: diagnois and management. http://www.nice.org.uk/guidance/CG127/NICEGuidance. Доступ: ноябрь 2016 г.

8. Fox KM; EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003;362:782-788.

9. Dezsi C. A. Differences in the clinical effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: a critical review of the evidence. Am J Cardiovasc Drugs 2014;14 (3):167-173.

10. PROGRESS Collaborative Group. Randomised trial of a perin-dopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack. Lancet 2001;358:1033-1041.

11. ADVANCE Collaborative Group. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet 2007;370:829-840.

12. Beckett N. S., Peters R., Fletcher A. E. et al. (HYVET): Treatment of hypertension in patients 80 years of age or older. N Engl J Med 2008;358:1887-1898. DOI: 10.1056/NEJMoa0801369.